Jefferies Group’s Teva Pharmaceuticals TEVA Stock Holding History

Jefferies Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.09M	Sell	258,664 -16,965	-6%	-$150K	0.02%	591
2022 Q2	$2.07M	Buy	275,629 +164,670	+148%	+$1.43M	0.02%	604
2022 Q1	$1.04M	Buy	110,959 +76,010	+217%	+$634K	0.01%	877
2021 Q4	$280K	Buy	+34,949	New	+$315K	﹤0.01%	1309
2021 Q3	–	Sell	-15,822	Closed	-$148K	–	2020
2021 Q2	$157K	Buy	15,822 +4,822	+44%	+$51K	﹤0.01%	1436
2021 Q1	$127K	Sell	11,000 -28,000	-72%	-$321K	﹤0.01%	1428
2020 Q4	$376K	Sell	39,000 -89,483	-70%	-$857K	﹤0.01%	1225
2020 Q3	$1.16M	Buy	128,483 +6,077	+5%	+$64.3K	0.01%	752
2020 Q2	$1.51K	Buy	122,406 +113,509	+1,276%	+$1.28M	0.02%	657
2020 Q1	$80K	Sell	8,897 -30,098	-77%	-$308K	﹤0.01%	1825
2019 Q4	$382K	Buy	+38,995	New	+$348K	﹤0.01%	1968
2019 Q3	–	Sell	-79,335	Closed	-$732K	–	3039
2019 Q2	$732K	Sell	79,335 -15,643	-16%	-$189K	0.01%	1463
2019 Q1	$1.49M	Buy	94,978 +2,096	+2%	+$37K	0.01%	1059
2018 Q4	$1.43M	Buy	92,882 +88,593	+2,066%	+$1.82M	0.01%	985
2018 Q3	$92K	Sell	4,289 -75,000	-95%	-$1.74M	﹤0.01%	2229
2018 Q2	$1.93M	Buy	79,289 +75,000	+1,749%	+$1.53M	0.01%	911
2018 Q1	$73K	Buy	+4,289	New	+$83.7K	﹤0.01%	2099
2017 Q4	–	Sell	-43,855	Closed	-$772K	–	2803
2017 Q3	$772K	Sell	43,855 -98,179	-69%	-$2.21M	0.01%	1414
2017 Q2	$4.72M	Buy	142,034 +81,737	+136%	+$2.53M	0.03%	556
2017 Q1	$1.94M	Buy	60,297 +58,293	+2,909%	+$1.99M	0.01%	933
2016 Q4	$73K	Sell	2,004 -110,795	-98%	-$4.42M	﹤0.01%	2057
2016 Q3	$5.19M	Buy	112,799 +84,398	+297%	+$4.4M	0.03%	515
2016 Q2	$1.43M	Sell	28,401 -30,812	-52%	-$1.64M	0.01%	1016
2016 Q1	$3.17M	Sell	59,213 -28,964	-33%	-$1.7M	0.02%	656
2015 Q4	$5.79M	Buy	+88,177	New	+$5.45M	0.03%	408
2015 Q3	–	Sell	-13,425	Closed	-$870K	–	2997
2015 Q2	$794K	Sell	13,425 -1,152,577	-99%	-$71.1M	﹤0.01%	1349
2015 Q1	$72.6M	Buy	+1,166,002	New	+$67.8M	0.41%	31
2014 Q4	–	Sell	-43,159	Closed	-$2.4M	–	2322
2014 Q3	$2.32M	Sell	43,159 -491,106	-92%	-$26M	0.02%	667
2014 Q2	$28M	Buy	534,265 +1,993	+0.4%	+$102K	0.24%	82
2014 Q1	$28.1M	Buy	532,272 +310,616	+140%	+$14.4M	0.27%	61
2013 Q4	$8.88M	Buy	221,656 +171,771	+344%	+$6.76M	0.06%	188
2013 Q3	$1.88M	Buy	+49,885	New	+$1.95M	0.02%	626

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Jefferies Group's TEVA Position: Q3 2022 in Review

Jefferies Group reduced its Teva Pharmaceuticals (TEVA) stake by 6.2% in Q3 2022, selling an estimated $150K and leaving 258,664 shares worth $2.09M. The position accounts for 0.02% of the portfolio, ranked #591.

Jefferies Group first reported a position in TEVA in Q3 2013 and has held it in 32 quarters since. The position peaked at $72.6M in Q1 2015. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

Jefferies Group held 258,664 shares of Teva Pharmaceuticals worth $2.09M as of Q3 2022.
Jefferies Group sold 16,965 Teva Pharmaceuticals shares in Q3 2022, an estimated $150K.
Teva Pharmaceuticals made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #591 holding.
Jefferies Group first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 32 quarters since.
Jefferies Group's Teva Pharmaceuticals position peaked at $72.6M in Q1 2015.
430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.